Werewolf Therapeutics and privately held Ambros Therapeutics have agreed to merge in an all-stock transaction that will create a Nasdaq-listed biotechnology company centered on neridronate, an investigational treatment in a pivotal Phase 3 trial for complex regional pain syndrome type 1. A concurrent oversubscribed $150 million private placement is expected to fund the combined company through topline CRPS-RISE results anticipated in 2028, a planned New Drug Application to the United States Food and Drug Administration and initial commercial preparations, with projected cash runway into the first half of 2029. The transaction therefore gives Ambros Therapeutics both a public listing and enough expected capital to answer the central question surrounding neridronate: whether a more precisely selected CRPS-1 population can produce the pivotal efficacy result needed for a potential first United States approval in a disease with no FDA-approved pharmacological treatment.
Under the agreement, Ambros Therapeutics is valued at approximately $500 million before the financing while Werewolf Therapeutics carries an implied value of $47.5 million. Existing Ambros Therapeutics shareholders are expected to own approximately 71.7% of the combined company, investors participating in the $150 million financing about 21.5%, and existing Werewolf Therapeutics shareholders approximately 6.8%, subject to adjustments tied to Werewolf Therapeutics’ closing cash position. The transaction is expected to close by the first quarter of 2027, after which the company would operate as Ambros Therapeutics and trade on Nasdaq under the ticker AMBX.
CRPS-RISE could support a U.S. filing from a single successful Phase 3 trial
Ambros Therapeutics is currently enrolling approximately 270 adults in CRPS-RISE, a multicenter, randomized, triple-blind and placebo-controlled Phase 3 study designed to evaluate intravenous neridronate in patients with relatively early, warm-phase CRPS-1. Participants are randomized equally to four 100-milligram neridronate infusions or placebo administered during a 10-day period, with change in pain intensity from baseline through week 12 serving as the primary efficacy endpoint. Additional measures examine pain reduction, patient-reported outcomes and longer-term disease status.
Ambros Therapeutics said previous interactions with the FDA indicate that one successful pivotal study such as CRPS-RISE could potentially provide sufficient clinical evidence to support a marketing application. Neridronate already has FDA Breakthrough Therapy, Fast Track and Orphan Drug designations, potentially giving the company additional regulatory interaction and incentives if the trial succeeds. These designations do not establish efficacy or guarantee approval, and the planned single-trial pathway remains dependent on the magnitude, reliability and overall benefit-risk profile of the Phase 3 result.
CRPS-1 is an unusually difficult pain disorder that often begins following an injury to an arm or leg and can produce severe continuous pain, swelling, temperature changes and extreme sensitivity. Ambros Therapeutics estimates approximately 65,000 people are newly diagnosed annually in the United States. The condition often begins with an inflammatory warm phase before some patients progress toward a more chronic cold phase characterized by persistent pain and functional impairment.
The CRPS-RISE strategy concentrates specifically on patients whose disease has been present for six months or less, who exhibit characteristics of the warm CRPS-1 phenotype and who have positive triple-phase bone scans. That unusually narrow selection strategy is central to the development program because Ambros Therapeutics believes those characteristics identify a biological population more likely to respond to neridronate.
Earlier neridronate studies showed strong pain relief but previous Phase 3 development also encountered futility
Neridronate is not a newly discovered molecule. The bisphosphonate was developed by Abiogen Pharma and is already approved in Italy for CRPS and several other bone disorders. Ambros Therapeutics estimates that approximately 600,000 patients have received neridronate across its approved Italian indications, giving the medicine a considerably larger human exposure history than is typical for a United States Phase 3-stage biotechnology asset.
Earlier randomized research also produced substantial efficacy signals. An 82-patient placebo-controlled study published in Rheumatology evaluated four intravenous 100-milligram neridronate infusions over 10 days in patients with acute CRPS-1. Pain declined substantially more with neridronate than placebo, with investigators reporting a 46.5-millimeter reduction on a visual analogue scale versus 22.6 millimeters with placebo by day 40. Improvements were also observed across other pain and quality-of-life measures.
A separate randomized study involving 78 patients tested intramuscular neridronate and similarly reported greater pain reduction than placebo. Nearly 66% of neridronate recipients achieved at least a 50% reduction in pain compared with approximately 30% receiving placebo, while improvements were also observed in allodynia, hyperalgesia and pain with movement.
The clinical history is not uniformly positive, however. Two later Phase 3 programs sponsored by Grünenthal were terminated early in 2019 after a pooled interim analysis indicated futility. ClinicalTrials.gov records for one of those studies show that the sponsor stopped recruitment because the interim results suggested a low probability that the trials would demonstrate the planned pain benefit.
In another terminated study, the reported week-12 least-squares mean change in average pain intensity was minus 1.28 points with intravenous neridronate and minus 1.71 points with placebo, meaning the active arm did not demonstrate superiority on the primary endpoint in the available analysis.
That history makes CRPS-RISE particularly consequential. Ambros Therapeutics is not simply repeating the previous broad Phase 3 strategy and hoping for a different outcome. The new study deliberately enriches enrollment for patients with recent-onset warm CRPS-1 and positive triple-phase bone scans, reflecting the hypothesis that previous studies may have included biologically heterogeneous patients who were unlikely to benefit from neridronate.
Whether that precision-selection approach actually solves the previous efficacy problem remains unproven. CRPS-RISE therefore represents both an opportunity to validate earlier positive studies and a direct test of whether identifying a narrower responder population can overcome the later Phase 3 failures.
$150m financing could carry the combined company through both Phase 3 data and an FDA submission
The concurrent private placement is unusually important because it removes much of the near-term financing uncertainty around the pivotal program. RA Capital Management and Janus Henderson Investors are co-leading the $150 million financing, with participation from healthcare-focused investors including Aberdeen Investments, Adage Capital Partners, ADAR1 Capital Management, Patient Square Capital’s Enavate Sciences platform and several others.
The companies expect the financing and existing resources to support operations through the CRPS-RISE topline result in 2028, a subsequent planned NDA submission and commercial preparation, with runway into the first half of 2029. That means investors should not have to evaluate neridronate against an obvious near-term requirement for another major capital raise merely to reach the pivotal efficacy result, although future financing needs would depend on trial timing, regulatory requirements and commercialization spending.
Ambros Therapeutics has also strengthened neridronate’s intellectual-property position. A United States patent application covering selection of CRPS-1 patients using positive triple-phase bone scans and characteristics of the warm disease subtype received a Notice of Allowance earlier in 2026, potentially supporting market exclusivity through 2045. The patent strategy closely mirrors the clinical-enrichment criteria being used in CRPS-RISE, linking the company’s precision-medicine development approach with its potential future commercial protection.
Werewolf Therapeutics’ existing oncology programs will not form the primary strategic focus of the combined business. Current Werewolf Therapeutics shareholders will instead receive contingent value rights providing potential participation in proceeds generated if pre-transaction assets, including its conditionally activated immunotherapy programs, are sold or otherwise monetized.
Werewolf Therapeutics shares more than double as investors reprice the company around Ambros and neridronate
Investor reaction was immediate. Werewolf Therapeutics shares more than doubled during August 21 trading after announcement of the merger and concurrent financing, following an even larger premarket surge. Market reports showed the stock gaining roughly 114% during morning trading, reflecting a dramatic revaluation of a company that had previously been exploring strategic alternatives.
The rally is understandable because existing Werewolf Therapeutics shareholders are exchanging exposure to a small oncology developer facing strategic uncertainty for an interest in a fully financed, late-stage rare-disease company. However, their expected 6.8% ownership means most of the combined company’s economics will belong to existing Ambros Therapeutics investors and participants in the new financing.
The clinical risk also remains substantial despite the financing and regulatory designations. Neridronate has compelling positive studies, extensive real-world exposure in Italy and a clearly defined biological rationale, but it also carries the unusual baggage of previous Phase 3 programs that were stopped for futility. CRPS-RISE is therefore testing something more specific than whether neridronate reduces pain. It must demonstrate that Ambros Therapeutics has correctly identified the patient population in which that benefit becomes reliably reproducible.
A positive 2028 result could establish a clear path toward what Ambros Therapeutics believes may become the first FDA-approved pharmacological treatment for CRPS-1, supported by a single short treatment cycle of four intravenous infusions and potentially long-lived intellectual-property protection. A negative result would raise much harder questions because the combined company will have been built and financed primarily around this one late-stage clinical thesis.
